Comerica Bank Buys 30,155 Shares of Enovis Corporation $ENOV

Comerica Bank increased its position in Enovis Corporation (NYSE:ENOV) by 57.9% in the 4th quarter, HoldingsChannel reports. The fund owned 82,274 shares of the company’s stock after buying an additional 30,155 shares during the quarter. Comerica Bank’s holdings in Enovis were worth $2,192,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. Farther Finance Advisors LLC boosted its position in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. GAMMA Investing LLC lifted its stake in shares of Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Enovis by 235.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after buying an additional 1,195 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new position in Enovis in the 3rd quarter worth $64,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of NYSE ENOV opened at $24.11 on Wednesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The company has a market cap of $1.39 billion, a P/E ratio of -1.16 and a beta of 1.41. The firm’s fifty day moving average is $23.73 and its two-hundred day moving average is $25.88. Enovis Corporation has a 52-week low of $21.00 and a 52-week high of $37.85.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis Corporation will post 3.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ENOV. Evercore reissued an “outperform” rating on shares of Enovis in a report on Monday, January 12th. BTIG Research upped their price objective on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Wells Fargo & Company raised Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, William Blair started coverage on Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $47.43.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders bought 5,000 shares of company stock valued at $121,983 in the last quarter. 2.90% of the stock is currently owned by insiders.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.